Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.
Article Details
- CitationCopy to clipboard
Lamoth F
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.
Infect Drug Resist. 2023 Feb 22;16:1087-1097. doi: 10.2147/IDR.S375625. eCollection 2023.
- PubMed ID
- 36855391 [ View in PubMed]
- Abstract
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-hospital morbidity and mortality. The limited number of antifungal drug classes and the emergence of multi-resistant Candida species, such as Candida auris and some Candida glabrata isolates, is concerning. However, recent advances in antifungal drug development provide promising perspectives for the therapeutic approach of IC. Notably, three novel antifungal agents, currently in Phase II/III clinical trials, are expected to have an important place for the treatment of IC in the future. Rezafungin is a novel echinocandin with prolonged half-life. Ibrexafungerp and fosmanogepix are two first-in-class antifungal drugs with broad spectrum activity against Candida spp., including C. auris and echinocandin-resistant species. These novel antifungal agents also represent interesting alternative options because of their acceptable oral bioavailability (ibrexafungerp and fosmanogepix) or their large interdose interval (once weekly intravenous administration for rezafungin) for prolonged and/or outpatient treatment of complicated IC. This review discusses the potential place of these novel antifungal drugs for the treatment of IC considering their pharmacologic properties and their preclinical and clinical data.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Rezafungin 1,3-beta-glucan synthase component FKS1 Protein Aspergillus niger (strain CBS 513.88 / FGSC A1513) YesInhibitorDetails Rezafungin 1,3-beta-glucan synthase component GSC2 Protein Baker's yeast YesInhibitorDetails